Business
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2025
TOULOUSE, France & FULLERTON, Calif., February 26, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today provided an update on business and cash flow for the fourth quarter ended December 31, 2025.
About this update from Abionyx Pharma Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Consolidated revenue of €4.1 million at the end of December 2025","length":64,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash position of €3.5 million as of December 31, 2025","length":53,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash runway through year-end 2026 excluding France 2030 non-dilutive funding","length":76,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":193,"olType":false},{"type":"text","content":"TOULOUSE, France & FULLERTON, Calif., February 26, 2026--(BUSINESS WIRE)--Regulatory News:","length":94,"tagName":"p"},{"type":"text","content":"ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today provided an update on business and cash flow for the fourth quarter ended December 31, 2025.","length":311,"tagName":"p"},{"type":"text","content":"The business dedicated to the discovery and development of innovative therapies, particularly in sepsis and the rare diseases LCAT deficiency and Norum disease, has not yet generated any revenue this quarter. ABIONYX Pharma continues to provide its bioproduct free of charge in response to compassionate use authorization (CUA) requests for Norum disease.","length":355,"tagName":"p"},{"type":"text","content":"The ABIONYX Pharma group recorded consolidated revenue of €4.1 million at the end of 2025, which relates solely to its subsidiary IRIS Pharma's contract research organization (CRO) activity in ophthalmology. The group did not commission any studies from IRIS Pharma in 2025.","length":278,"tagName":"p"},{"type":"text","content":"As of December 31, 2025, ABIONYX Pharma's cash position stood at €3.5 million to be compared to €3.2 million in 2024. The Company notes that it was selected for the France 2030 plan's "i-Démo" call for projects and has obtained €8.7 million in government support to combat sepsis, the third leading cause of death worldwide, of which €6.5 million is still to be received. On a standalone basis, excluding this non-dilutive funding, the Company’s cash runway extends through year-end 2026.","length":506,"tagName":"p"},{"type":"text","content":"Selected financial information ...